Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
González-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
All venous thrombosis clinical trials
|
|
González-Fajardo study, 2008
|
|
Treatments
Studied treatment |
long-term anticoagulant treatment with enoxaparin during at least 3 months
enoxaparin once daily in fixed doses (4000 anti-Xa units, 40
mg)
|
Control treatment |
long-term anticoagulant treatment with coumarin during at least 3 months
targetet international normalized ratio [INR], 2-3
|
Patients
Patients |
patients with symptomatic, unilateral, first-episode DVT |
Method and design
Randomized effectives |
85 / 80 (studied vs. control) |
Design |
Parallel groups |
Blinding |
open, blind assessment |
Follow-up duration |
1y, 5y |
Number of centre |
single center |
Geographic area |
Spain |
Primary endpoint |
incidence of post-thrombotic syndrome |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
VTE during active anticoagulant treatment
NA / 85
NA / 80
classic
1,97 [1,06;3,66]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Studied treat. |
Control treat. |
The primary endpoint (if exists) appears in blod characters
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Reference(s)
-
González-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C.
Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin..
J Vasc Surg 2008;48:953-9
Pubmed
|
Hubmed
| Fulltext
|